100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Anna Törner: “My quantified life”

“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Did you know that not every sphere is really a round sphere?

ZEISS Metrology Expert Tip.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

The Future of Swedish & Danish Life Science

Venom from the deathstalker carries radiopharmaceuticals to the brain

In order to target cancerous brain tumours with radionuclides, the problematic blood-brain barrier must first be crossed. Life Science Sweden has visited a KI r...

This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”

This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understan...

GU Ventures AB

Obesity-drug pioneers win Lasker Award

This year’s Lasker Prize in Clinical Research has been awarded to three researchers for their discoveries in GLP-1-based drugs that, according to the jury, “hav...

Orbán's extended arm becomes health commissioner in the EU

Hungarian Olivér Várhelyi may soon become the most influential official for the healthcare and pharmaceutical industry in the EU. Várhelyi, who is close to Hung...

The new Swedish life science strategy – “It will consolidate Sweden as a leader”

Clinical trials and precision health are emphasised as key areas in the new national life science strategy.

GSK pays 2.2 billion dollars to settle Zantac lawsuits

British drugmaker Glaxo Smith Kline, GSK, has struck a 2.2 billion dollar settlement, thereby resolving a vast majority of the liability cases pending against t...

New large lab building in Lund inaugurated – here are the companies moving in

Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employme...

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Sobi announces agreement with Enable Injections

Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.

Explore our tailored program for Control 2025

Choose an innovation tour, or join our industry-specific guided tours.

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

ZEISS receives FDA clearance for INTRABEAM 700

With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...